HC Wainwright Has Negative Forecast for MBOT FY2027 Earnings

Key Points

• HC Wainwright lowered its FY2027 EPS estimate for Microbot Medical to a loss of $0.29 per share from $0.28, while maintaining a “Buy” rating and a $12 price target.
• Microbot Medical’s latest quarterly results matched expectations with an $0.08-per-share loss, while revenue of $0.24 million exceeded the $0.13 million forecast.
• Analyst sentiment remains mixed but leans positive: MarketBeat reports a “Moderate Buy” consensus rating from seven analysts and an average price target of $5.08, compared with the stock’s recent $0.94 price.

Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - HC Wainwright dropped their FY2027 earnings estimates for Microbot Medical in a research note issued to investors on Wednesday, October 21st. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.29) per share for the year, down from their prior estimate of ($0.28). HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Microbot Medical's current full-year earnings is ($0.30) per share.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The company had revenue of $0.24 million during the quarter, compared to analysts' expectations of $0.13 million.

MBOT has been the subject of a number of other research reports. Citigroup initiated coverage on Microbot Medical in a research report on Friday. They set a "market outperform" rating for the company. Zacks Research lowered shares of Microbot Medical from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Microbot Medical in a report on Friday, October 2nd. UBS Group set a $2.50 price target on shares of Microbot Medical in a research note on Friday. Finally, B. Riley Financial started coverage on shares of Microbot Medical in a report on Friday, September 11th. They set a "buy" rating and a $4.00 price target for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.08.

Microbot Medical Stock Up 0.2%

Shares of NASDAQ:MBOT opened at $0.94 on Friday. The company has a market capitalization of $63.27 million, a P/E ratio of -3.92 and a beta of 1.05. Microbot Medical has a 52-week low of $0.93 and a 52-week high of $2.85. The stock's fifty day simple moving average is $1.30 and its 200-day simple moving average is $1.72.

Institutional Trading of Microbot Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MBOT. Bank of America Corp DE lifted its holdings in shares of Microbot Medical by 1,688.1% during the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company's stock worth $183,000 after acquiring an additional 71,560 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Microbot Medical in the fourth quarter worth approximately $65,000. Private Advisor Group LLC purchased a new stake in Microbot Medical in the first quarter valued at approximately $54,000. Cetera Investment Advisers grew its holdings in Microbot Medical by 44.7% in the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 13,099 shares during the period. Finally, CTC Alternative Strategies Ltd. acquired a new position in Microbot Medical during the first quarter worth approximately $28,000. Hedge funds and other institutional investors own 16.30% of the company's stock.

About Microbot Medical

Microbot Medical Inc NASDAQ: MBOT is a medical device company developing robotic and computer-assisted technologies for minimally invasive endovascular procedures. The company focuses on systems intended to help physicians navigate blood vessels and deliver interventional devices while potentially improving procedural control and reducing radiation exposure to medical personnel.

Microbot Medical's primary product candidate is the LIBERTY Endovascular Robotic System, a single-use, disposable robotic platform designed to remotely control guidewires and catheters during vascular procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.